We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Says Brand and Generic Opioid Painkillers Must Have REMS
FDA Says Brand and Generic Opioid Painkillers Must Have REMS
February 13, 2009
The FDA told 16 drugmakers that it will require risk evaluation and mitigation strategies (REMS) to help prevent abuse of opioid pain products such as transdermal patches.